Investigators performed a metabolic drug screen to identify leukemic stem cell (LSC)-specific vulnerabilities and found that nicotinamide phosphoribosyltransferase inhibitors selectively killed LSCs, while sparing normal hematopoietic stem and progenitor cells.
[Cell Stem Cell]
Sorry, but the selected Zotpress account can't be found.
